The New York-based pharma giant announced that its experimental vaccine was more than 90 per cent effective in preventing COVID, based on an interim data analysis.
Vast wealth and the promise of dramatic change make for cautious optimism concerning Saudi Arabia, the chief executive…20 Views | the publication reaches you by | Saudi Arabia Today
Pfizer’s vaccine is an anti-viral messenger RNA shot for active immunisation against COVID-19 administered as intramuscular injection.
A statement released October 16, 2020 (Friday) suggested the company’s coronavirus vaccine candidate could be ready for distribution throughout the US by the end of November.
This May 4, 2020, file photo shows the first patient enrolled in Pfizer’s COVID-19 vaccine clinical trial at the University of Maryland School of Medicine in Baltimore.
Pfizer said the interim analysis was conducted after 94 participants in the trial developed COVID-19, examining how many of them received the vaccine versus a placebo.
“I’m near ecstatic,” Bill Gruber, one of Pfizer’s top vaccine scientists, told Reuters in an interview. “This is a great day for public health and for the potential to get us all out of the circumstances we’re now in.
The project for the design, engineering and procurement of the new 400,000m3/day Jubail II seawater reverse osmosis (SWRO)…4 Views | the publication reaches you by | Saudi Arabia Today
Do you have information you want to reach our readers?